Vertex (VRTX) Seen as Top Large-Cap Biotech Growth Idea at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Baird Remains Bullish on Vertex Pharma (VRTX) Ahead of 3Q Results and Orkambi Launch
October 27, 2015 9:24 AM EDTBaird reiterated an Outperform rating and $160.00 price target on Vertex (NASDAQ: VRTX) ahead of the company's 3Q15 earnings results and Orkambi launch. Baird's interaction with physicians at the NACF conference earlier this month reaffirmed views that Orkambi will have a strong launch. VRTX is... More
Vertex Pharma (VRTX) and CRISPR Enter Collaboration Related to Gene Editing Technology
October 26, 2015 8:44 AM EDTVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics today announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPRs gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. The collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics. Vertex and CRISPR will focus their initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to... More
